Anixa reports extended survival in ovarian cancer CAR-T trial; regulatory approval for 100x dose escalation

Anixa Biosciences Inc

12 patients treated; 7 lived beyond expected median survival of 3-4 months; one survived 28 months.
No dose-limiting toxicities; protocol amended to escalate from 1x10^7 to up to 1x10^9 cells/kg (100x increase).
Next cohort includes lymphodepletion to potentially enhance CAR-T efficacy in solid tumors.
Three patients remain alive at 15, 14, and 8 months post-treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.